Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in the treatment of autism
IRCT201204081556N40Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of galantamine in Autism Spectrum Disorder (ASD), sponsored by Tehran University of Medical Sciences. Started Apr 2012; status: completed.
02
Drugs
galantamine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT201204081556N40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201204081556N40.